Printer Friendly

CIVIL ACTION FILED AGAINST EPITOPE

 CIVIL ACTION FILED AGAINST EPITOPE
 BEAVERTON, Ore., June 21 /PRNewswire/ -- Epitope, Inc.


(AMEX: EPT), announced that it has been served with a complaint filed in the U.S. District Court for the District of Oregon by a plaintiff who seeks to represent a purported class of Epitope shareholders. The complaint seeks unspecified damages from the company and certain of its executive officers and directors based on alleged misstatements and omissions related to the company's application for FDA approval of its OraSure(R) product.
 "We believe the allegations contained in the complaint are based on an unfortunate misinterpretation of statements taken out of context from internal FDA documents. The company is discussing the complaint with counsel and intends to vigorously defend the action," said Adolph J. Ferro, Epitope's president and chief executive officer.
 -0- 6/21/92
 /CONTACT: Mary Hagen, 503-641-6115 or Shari Annes, 415-726-5400, both of Epitope/
 (EPT) CO: Epitope, Inc. ST: Oregon IN: MTC SU:


JP -- NYONS1 -- 2185 06/21/92 21:45 EDT
COPYRIGHT 1992 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1992 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Jun 21, 1992
Words:165
Previous Article:'BATMAN RETURNS' SOARS WITH HISTORY-MAKING $46.5 MILLION OPENING
Next Article:NEW SCHERING-PLOUGH BROCHURE PROVIDES SOLUTION TO SUMMER SKIN PROBLEMS


Related Articles
EPITOPE SETTLES CLASS ACTION LITIGATION
EXERCISE PRICE SET FOR EPITOPE WARRANTS TO BE ISSUED FOR CLASS ACTION SETTLEMENT
EPITOPE SUES BROKER/ANALYST FOR DEFAMATION, SECURITIES FRAUD AND STOCK MANIPULATION
EPITOPE AND KIPKE SETTLE LAWSUIT
EPITOPE RECEIVES FDA APPROVAL TO MARKET ORASURE DEVICE
Epitope Sues to Rescind A&W Acquisition
Epimmune Awarded National Cancer Institute Grant for Development of a Multi-Epitope Vaccine for Ovarian and Breast Cancer.
Epimmune Receives NIH Contract Amendment to Include Smallpox as A Target of Its High Throughput Approach Toward Development Of Epitope-Based Vaccines.
Epimmune Provides Preliminary Cancer Trial Data at ASCO Meeting.
Epimmune Awarded National Cancer Institute Grant to Support Analysis of Immune Response in Patients Immunized With Multi-Epitope Cancer Vaccine.

Terms of use | Copyright © 2017 Farlex, Inc. | Feedback | For webmasters